Eli Lilly stock soars 15% after topping second-quarter expectations

Eli Lilly stock catapulted 15% in one day after topping second-quarter expectations amid fresh enthusiasm for weight-loss drugs.

LLY stock blew through a buy zone and is trading at a record high.

Mounjaro, cancer treatment Verzenio , diabetes drug Jardiance and autoimmune medicine Taltz all topped forecasts.

Lilly 's adjusted earnings soared almost 69% to $ 2.11 per share in the second quarter .

Eli Lilly stock broke out Aug. 8 when the stock shot up 67.52 , or 15% , to 521.60 .

Eli Lilly is angling for FDA approval of donanemab , a potential Alzheimer's treatment that removes built-up plaque in the brain known as beta amyloid.

Novo Nordisk said in August its obesity drug Wegovy cut the risk of cardiovascular events.

It will be key to watch how the markets for weight-loss drugs and Alzheimer's treatments unfold. Follow Allison Gatlin on Twitter at @IBD_AGatlin. YOU MAY ALSO LIKE:.